Phase III Study of ABI-007(Albumin-bound Paclitaxel)

[1] Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas. Clinicaltrials.gov Website. Last Accessed February 1, 2016 (NCT00844649)
[2] Schmidt SL, Durkal V, Jayavalsan SP, Ritch PS, Thomas JP, Erickson B, Christians KK, et al. Can the sequence of chemotherapy regimens influence outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)? J Clin Oncol 34, 2016 (suppl 4S; abstr 428)
[3] Jayavalsan SP, Schmidt SL, Durkal V, Ritch PS, Thomas JP, Erickson B, Christians KK, et al. Can response to treatment predict outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)? J Clin Oncol 34, 2016 (suppl 4S; abstr 443)
[4] Hidalgo M, Cooray P, Carrato A, Jameson MB, Parnis F, Jeffery M, Grimison PS. et al. A phase 1b study of the anti-cancer stem cell agent demcizumab and gemcitabine +/- nab-paclitaxel in patients with PC (Abstract 341) J Clin Oncol 34, 2016 (suppl 4S; abstr 341)
[5] Shahda S, El-Rayes BF, O’Neil BH, Starodub A, Hanna WT, Borodyansky L, Oh C, et al.A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).J Clin Oncol 34, 2016 (suppl 4S; abstr 284)
[6] Firdaus I, Waterhouse DM, Gutierrez M, Wainberg ZA, George B, Kelly K, Bekaii-Saab TS, et al.>nab-paclitaxel (nab) + nivolumab (Nivo) ? gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).J Clin Oncol 34, 2016 (suppl 4S; abstr TPS475)
[7]Tempero MA, Coussens LM, Fong L, Manges R, Singh P, Li Y, Cole GW, James DF, et al.A randomized, multicenter, double-blind, placebo-controlled study of the Bruton tyrosine kinase inhibitor, ibrutinib, versus placebo in combination with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).J Clin Oncol 34, 2016 (suppl 4S; abstr TPS483)
[8] Hingorani SR, Harris WP, Seery TE, Zheng L, Sigal D, HendifarAE, Braiteh FS, et al. Interim results of a randomized phase 2 study of PEGPH20 added to nab?paclitaxel/gemcitabine in patients with stage 4 previously untreated pancreatic cancer. J Clin Oncol 34, 2016 (suppl 4S; abstr 439)